Drug Trial Radar · NCT06822426
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 14, 2025
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- CorMedix TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Conditions
- Central Line Associated Blood Stream Infections (CLABSI)
Interventions
(taurolidine and heparin) catheter lock solutionDrug
for central venous catheter installation use
HeparinDrug
Heparin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the studyTime frame: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California · Recruiting
MedStar Health Research Institute
Washington D.C., District of Columbia · Recruiting
Bioresearch Partner
Doral, Florida · Recruiting
Emory University Hospital - GCRC
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
Johns Hopkins Clinical Research Unit
Baltimore, Maryland · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
NYU Grossman School of Medicine
New York, New York · Not yet recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Duke University Hospital
Durham, North Carolina · Withdrawn
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
Vanderbilt Center for Human Nutrition
Nashville, Tennessee · Recruiting
Alchemi - Sugarland
Sugarland, Texas · Recruiting
Hacettepe University Hospitals
Altındağ, Ankara, Turkey (Türkiye) · Recruiting
Ankara University Ibni Sina Research and Application Hospital
Çankaya, Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent City Hospital
Çankaya, Ankara, Turkey (Türkiye) · Recruiting
Hacettepe University Hospitals
Yenimahalle, Ankara, Turkey (Türkiye) · Recruiting
Istanbul University Faculty of Medicine, Capa State Hospital
Istanbul, Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.